EcoDrugPlus

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit

Ensembl ID : ENSMSIG00000028408
Gene Symbol: CACNA1D
1 Cross references
296 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit

Ensembl ID : ENSMSIG00000013188
Gene Symbol: CACNA1S
1 Cross references
274 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit

Ensembl ID : ENSMSIG00000025204
Gene Symbol: CACNA1B
1 Cross references
298 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit

Ensembl ID : ENSMSIG00000013335
Gene Symbol: CACNA1A
1 Cross references
299 Possible Orthologues:

Calcium Channel, Voltage-Dependent, R Type, Alpha 1e Subunit

Ensembl ID : ENSMSIG00000013099
Gene Symbol: CACNA1E
1 Cross references
309 Possible Orthologues:

Calcium Channel, Voltage-Dependent, T Type, Alpha 1g Subunit

Ensembl ID : ENSMSIG00000007636
Gene Symbol: CACNA1G
1 Cross references
211 Possible Orthologues:

Calcium Channel, Voltage-Dependent, T Type, Alpha 1h Subunit

Ensembl ID : ENSMSIG00000012417
Gene Symbol: CACNA1H
1 Cross references
216 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 1i Subunit

Ensembl ID : ENSMSIG00000028818
Gene Symbol: CACNA1I
1 Cross references
279 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2

Ensembl ID : ENSMSIG00000017575
Gene Symbol: CACNA2D2
1 Cross references
287 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 4

Ensembl ID : ENSMSIG00000008776
Gene Symbol: CACNA2D4
1 Cross references
332 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha2/delta Subunit 1

Ensembl ID : ENSMSIG00000018142
Gene Symbol: CACNA2D1
1 Cross references
300 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha2/delta Subunit 3

Ensembl ID : ENSMSIG00000028244
Gene Symbol: CACNA2D3
1 Cross references
324 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).